ly3471851
Recombinant proteinexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2017 (NCT04380324)
Timeline
Indications
Mechanism of action
- Interleukin-2 receptor alpha chainINHIBITOR
IL2RA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05565729 | Phase 1 | Oct 5, 2022 | Eli Lilly, Nektar Therapeutics |
| NCT04998487 | Phase 1 | Aug 16, 2021 | Eli Lilly |
| NCT04677179 | Phase 2 | Jan 11, 2021 | Eli Lilly |
| NCT04433585 | Phase 2 | Aug 4, 2020 | Eli Lilly, Nektar Therapeutics |
| NCT04119557 | Phase 1 | Oct 28, 2019 | Eli Lilly, Nektar Therapeutics |
| NCT04133116 | Phase 1 | Oct 27, 2019 | Eli Lilly, Nektar Therapeutics |
| NCT04081350 | Phase 1 | Oct 14, 2019 | Eli Lilly, Nektar Therapeutics |
| NCT03556007 | Phase 1 | May 1, 2018 | Eli Lilly, Nektar Therapeutics |
| NCT04380324 | Phase 1 | Mar 16, 2017 | Eli Lilly, Nektar Therapeutics |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 9 | 7 | 2 | 2017 |
| Nektar Therapeutics | For profit | 7 | 2 | 2 | 2017 |
2 organizations
Page 1 / 1